Pulse BiosciencesPLSE +7.44%31 EBITDA Margin % is -4,711.97% as of Mar. 2026. GuruFocus rates PLSE with a GF Score™ of 31/100. The stock has 3 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Pulse Biosciences ranks worse than 98.77% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Pulse Biosciences's EBITDA for the
three
months ended in Mar. 2026 was $-18.90 Mil. Pulse Biosciences's Revenue for the
three
months ended in Mar. 2026 was $0.40 Mil. Therefore, Pulse Biosciences's EBITDA margin for the quarter that ended in Mar. 2026 was -4,711.97%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Pulse Biosciences EBITDA Margin % Related Terms
Pulse Biosciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Pulse Biosciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PLSE vs NNNN, STAA, ATRC: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Pulse Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pulse Biosciences EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Pulse Biosciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Pulse Biosciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pulse Biosciences (PLSE) has a EBITDA Margin % of -4,711.97% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pulse Biosciences and its competitors. According to the industry distribution chart, Pulse Biosciences ranks #806 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 98.8%.
Is Pulse Biosciences' EBITDA Margin % too high?
Pulse Biosciences' current EBITDA Margin % is -4,711.97%. Based on the distribution chart, Pulse Biosciences ranks #806 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Pulse Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Pulse Biosciences' EBITDA Margin % compare to NNNN and STAA?
According to the Medical Devices & Instruments industry distribution chart, Pulse Biosciences ranks #806 out of 816 companies for EBITDA Margin %. This places Pulse Biosciences in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Pulse Biosciences and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pulse Biosciences's current EBITDA Margin % is -4,711.97%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pulse Biosciences stock overvalued right now?
Pulse Biosciences (PLSE) has a current EBITDA Margin % of -4,711.97%. The current EBITDA Margin % is -4,711.97%. Pulse Biosciences' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Pulse Biosciences (PLSE), the current EBITDA Margin % is -4,711.97% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.
31GF Score
Get the complete analysis for PLSE
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLSE has been successfully added to your 
